182 related articles for article (PubMed ID: 15928675)
21. Targeted therapy for oesophageal cancer: an overview.
Syrigos KN; Zalonis A; Kotteas E; Saif MW
Cancer Metastasis Rev; 2008 Jun; 27(2):273-88. PubMed ID: 18224295
[TBL] [Abstract][Full Text] [Related]
22. [Anticancer drug dosing--pharmacogenomic biomarkers or body surface area?].
Lehne G; Bjørheim J; Saeter G
Tidsskr Nor Laegeforen; 2007 Apr; 127(8):1040-4. PubMed ID: 17457389
[TBL] [Abstract][Full Text] [Related]
23. Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue.
Lee CK; Rowinsky EK; Li J; Giles F; Moore MJ; Hidalgo M; Capparelli E; Jolivet J; Baker SD
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2158-65. PubMed ID: 16609029
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics and pharmacogenomics in esophageal cancer chemoradiotherapy.
Sakaeda T; Yamamori M; Kuwahara A; Nishiguchi K
Adv Drug Deliv Rev; 2009 May; 61(5):388-401. PubMed ID: 19135108
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics of rituximab and its clinical use: thought for the best use?
Cartron G; Blasco H; Paintaud G; Watier H; Le Guellec C
Crit Rev Oncol Hematol; 2007 Apr; 62(1):43-52. PubMed ID: 17287129
[TBL] [Abstract][Full Text] [Related]
26. Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients.
Latz JE; Chaudhary A; Ghosh A; Johnson RD
Cancer Chemother Pharmacol; 2006 Apr; 57(4):401-11. PubMed ID: 16322991
[TBL] [Abstract][Full Text] [Related]
27. Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.
Kinders R; Parchment RE; Ji J; Kummar S; Murgo AJ; Gutierrez M; Collins J; Rubinstein L; Pickeral O; Steinberg SM; Yang S; Hollingshead M; Chen A; Helman L; Wiltrout R; Simpson M; Tomaszewski JE; Doroshow JH
Mol Interv; 2007 Dec; 7(6):325-34. PubMed ID: 18199854
[TBL] [Abstract][Full Text] [Related]
28. Critical issues in site-specific targeting of solid tumours: the carrier, the tumour barriers and the bioavailable drug.
Hamad I; Moghimi SM
Expert Opin Drug Deliv; 2008 Feb; 5(2):205-19. PubMed ID: 18248319
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant chemotherapy for early-stage breast cancer.
McArthur HL; Hudis CA
Hematol Oncol Clin North Am; 2007 Apr; 21(2):207-22. PubMed ID: 17512445
[TBL] [Abstract][Full Text] [Related]
30. Cytochrome P450s in the development of target-based anticancer drugs.
Purnapatre K; Khattar SK; Saini KS
Cancer Lett; 2008 Jan; 259(1):1-15. PubMed ID: 18053638
[TBL] [Abstract][Full Text] [Related]
31. Optimal controls for a model with pharmacokinetics maximizing bone marrow in cancer chemotherapy.
Ledzewicz U; Schättler H
Math Biosci; 2007 Apr; 206(2):320-42. PubMed ID: 16197967
[TBL] [Abstract][Full Text] [Related]
32. The role of nuclear receptors in pharmacokinetic drug-drug interactions in oncology.
Harmsen S; Meijerman I; Beijnen JH; Schellens JH
Cancer Treat Rev; 2007 Jun; 33(4):369-80. PubMed ID: 17451886
[TBL] [Abstract][Full Text] [Related]
33. The development of phase I cancer trial methodologies: the use of pharmacokinetic and pharmacodynamic end points sets the scene for phase 0 cancer clinical trials.
Calvert AH; Plummer R
Clin Cancer Res; 2008 Jun; 14(12):3664-9. PubMed ID: 18559580
[TBL] [Abstract][Full Text] [Related]
34. Population pharmacokinetic investigation of actinomycin-D in children and young adults.
Mondick JT; Gibiansky L; Gastonguay MR; Skolnik JM; Cole M; Veal GJ; Boddy AV; Adamson PC; Barrett JS
J Clin Pharmacol; 2008 Jan; 48(1):35-42. PubMed ID: 18094218
[TBL] [Abstract][Full Text] [Related]
35. Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference?
Mathijssen RH; de Jong FA; Loos WJ; van der Bol JM; Verweij J; Sparreboom A
Oncologist; 2007 Aug; 12(8):913-23. PubMed ID: 17766650
[TBL] [Abstract][Full Text] [Related]
36. Concept and clinical evaluation of carrier-mediated anticancer agents.
Zamboni WC
Oncologist; 2008 Mar; 13(3):248-60. PubMed ID: 18378535
[TBL] [Abstract][Full Text] [Related]
37. Review of clinical trials evaluating safety and efficacy of milk thistle (Silybum marianum [L.] Gaertn.).
Tamayo C; Diamond S
Integr Cancer Ther; 2007 Jun; 6(2):146-57. PubMed ID: 17548793
[TBL] [Abstract][Full Text] [Related]
38. [Genomic markers and anticancer chemotherapy].
Nishiyama M
Gan To Kagaku Ryoho; 2008 Feb; 35(2):194-9. PubMed ID: 18281756
[TBL] [Abstract][Full Text] [Related]
39. Antineoplastic drug monitoring.
Henner WD
Clin Lab Med; 1987 Sep; 7(3):625-39. PubMed ID: 3308299
[TBL] [Abstract][Full Text] [Related]
40. [Individual therapy in oncology].
Jaehde U
Med Monatsschr Pharm; 2003 May; 26(5):155-8. PubMed ID: 12784504
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
